Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, central African Republic

AIDS Research and Human Retroviruses

Volumn 28, Issue 4, 2012, Pages 315-323

  Péré, Hélène ^a,b   Charpentier, Charlotte ^c   Mbelesso, Pascal ^d,e   Dandy, Marius ^d   Matta, Mathieu ^a   Moussa, Sandrine ^f   De Dieu Longo, Jean ^e   Grésenguet, Gérard ^e   Abraham, Bruno ^g   Bélec, Laurent ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d Universitaire de Bangui   (Central African Republic)

^e Hôpital de l'Amitié   (Central African Republic)

^f INSTITUT PASTEUR DE BANGUI   (Central African Republic)

^g Service des Maladies Infectieuses   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CENTRAL AFRICA; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC RESISTANCE; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CENTRAL AFRICAN REPUBLIC; DNA FINGERPRINTING; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; MEDICATION ADHERENCE; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT; ZIDOVUDINE;

EID: 84859191049     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0127     Document Type: Article

References (27)

1. Joint United Nations Programme on HIV/AIDS. Global Report. AIDS epidemic update: December 2010. http://www.unaids.org/en/media/unaids/contentassets/ documents/unaidspublication/2010/20101123-globalreport-en.pdf.
2. Machuca A, Tang S, Hu J, et al.: Antiretroviral drug resistance and routine therapy, Cameroon. Increased genetic diversity and intersubtype recombinants of HIV-1 in blood donors from urban Cameroon. J Acquir Immune Defic Syndr 2007;45:361-363.
3. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, and Wensing AM: Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: A systematic review. Lancet Infect Dis 2010;10:155-166.
4. Marconi VC, Sunpath H, Lu Z, et al.: Prevalence of HIV-1 drug resistance after failure of a first highly active anti-retroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008;46:1589-1597.
5. Koyalta D, Charpentier C, Beassamda J, et al.: High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin Infect Dis 2009;49:155-159.
6. Tebit DM, Sangaré L, Makamtse A, et al.: HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso. J Acquir Immune Defic Syndr 2008;49:17-25.
7. Marcelin AG, Jarrousse B, Derache A, et al.: HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. AIDS 2007;21:2341-2343.
8. Charpentier C, Talla F, Nguepi E, Si-Mohamed A, and Bélec L: Virological failure and HIV type 1 drug resistance profiles among patients followed-up in private sector, Douala, Cameroon. AIDS Res Hum Retroviruses 2011;27:221-230.
9. Moussa S, Pinson P, Pelembi P, et al.: First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. AIDS Res Hum Retroviruses 2010;26: 1247-1248.
10. Marechal V, Jauvin V, Selekon B, et al.: Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: A 2005 study. AIDS Res Hum Retroviruses 2006;22:1036-1044.
11. Gody JC, Charpentier C, Mbitikon O, et al.: High prevalence of antiretroviral drug resistance mutations in non-B subtypes HIV-1 strains from African children receiving anti-retroviral therapy regimen according to the 2006 revised WHO recommendations. J Acquir Immune Defic Syndr 2008;49:566-570.
12. World Health Organization (WHO) recommendations: An-tiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings: Towards Universal Access. June 2006. http://www.who.int/hiv/pub/prev-care/en/ScalingUp- E.pdf.
13. Rouet F, Chaix ML, Nerrienet E, et al.: Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007;45:380-388.
14. Marcelin AG, Masquelier B, Descamps D, et al.: Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008; 52:3237-3243.
15. World Health Organization (WHO) recommendations: An-tiretroviral therapy for HIV infection in adults and adolescents. Antiretroviral therapy for a public health approach 2010 revision. http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf.
16. Laurent C, Kouanfack C, Vergne L, et al.: Antiretroviral drug resistance and routine therapy, Cameroon. Emerg Infect Dis 2006;12:1001-1004.
17. Turriziani O, Russo G, Lichtner M, et al.: Study of the geno-typic resistant pattern in HIV-infected women and children from rural west Cameroon. AIDS Res Hum Retroviruses 2008;24:781-785.
18. Kouanfack C, Montavon C, Laurent C, et al.: Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009;48:1318-1322.
19. Soria A, Porten K, Fampou-Toundji JC, et al.: Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther 2009;14:339-347.
20. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, and Deeks SG: Long-term consequences of the delay between virologic failure of highly active anti-retroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
21. Turner D, Brenner BG, Routy JP, Petrella M, and Wainberg MA: Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol 2004;27:31-39.
22. Paredes R, Sagar M, Marconi VC, et al.: In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 2009;83:2038-2043.
23. Boyer PL, Sarafianos SG, Arnold E, and Hughes SH: The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcrip-tase of human immunodeficiency virus type 1. J Virol 2002;76:3248-3256.
24. Ait-Khaled M, Stone C, Amphlett G, et al.: M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002;16:1686-1689.
25. Cotte L, Trabaud MA, Tardy JC, et al.: Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms. J Med Virol 2009;81: 672-677.
26. Scherrer AU, Hasse B, von Wyl V, et al.: Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: The Swiss HIV Cohort Study (SHCS). HIV Med 2009;10:647-656.
27. Maïga AI, Descamps D, Morand-Joubert L, et al.: Resistance- associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes. Antimicrob Agents Chemother 2010;54: 728-733.